In our experience, neither the use of the six anti-inflammatory factors CXCL2, CCL5, CCL22, IL-1RA, IL-10 and TGF-β found in SuperMApo (at their natural concentration or enriched threefold), nor the use of the 5 factors found to be complexed with TGF-β in SuperMApo were able to induce macrophage reprogramming or reproduce the therapeutic effect of SuperMApo in ongoing arthritis [26]. This evidence concerns the gene CCL22 and Arthritis.